X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
MYLAN
Dec-18
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2783,317-   
Low Rs8831,826-   
Sales per share (Unadj.) Rs228.41,526.4-  
Earnings per share (Unadj.) Rs10.441.4-  
Cash flow per share (Unadj.) Rs16.3327.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.81,651.3-  
Shares outstanding (eoy) m25.00514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.7 280.8%   
Avg P/E ratio x104.262.0 168.0%  
P/CF ratio (eoy) x66.47.9 845.5%  
Price / Book Value ratio x10.91.6 702.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,323,068 2.0%   
No. of employees `0001.435.0 3.9%   
Total wages/salary Rs m1,5350-   
Avg. sales/employee Rs Th4,210.922,438.2 18.8%   
Avg. wages/employee Rs Th1,132.20-   
Avg. net profit/employee Rs Th191.1609.3 31.4%   
INCOME DATA
Net Sales Rs m5,710785,337 0.7%  
Other income Rs m1230-   
Total revenues Rs m5,833785,337 0.7%   
Gross profit Rs m463203,216 0.2%  
Depreciation Rs m147147,046 0.1%   
Interest Rs m037,772 0.0%   
Profit before tax Rs m43818,398 2.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-2,927 -6.1%   
Profit after tax Rs m25921,325 1.2%  
Gross profit margin %8.125.9 31.3%  
Effective tax rate %40.8-15.9 -256.7%   
Net profit margin %4.52.7 167.1%  
BALANCE SHEET DATA
Current assets Rs m3,209438,531 0.7%   
Current liabilities Rs m2,070319,738 0.6%   
Net working cap to sales %20.015.1 132.0%  
Current ratio x1.61.4 113.1%  
Inventory Days Days7284 86.6%  
Debtors Days Days3593 37.4%  
Net fixed assets Rs m790152,342 0.5%   
Share capital Rs m50418 12.0%   
"Free" reserves Rs m2,4190-   
Net worth Rs m2,469849,591 0.3%   
Long term debt Rs m0916,981 0.0%   
Total assets Rs m4,6052,278,933 0.2%  
Interest coverage xNM1.5-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.20.3 359.8%   
Return on assets %5.62.6 217.0%  
Return on equity %10.52.5 418.0%  
Return on capital %17.73.2 557.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,7150-   
CASH FLOW
From Operations Rs m88163,193 0.1%  
From Investments Rs m-94-84,353 0.1%  
From Financial Activity Rs mNA-76,025 0.0%  
Net Cashflow Rs m-61,352 -0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 69.69 Rs / USD

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: ORCHID PHARMA LTD  IPCA LABS  FDC LTD.  NOVARTIS  SUN PHARMA  



Today's Market

Indian Indices End on a Strong Note; Sensex Ends 489 Points Higher(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views On News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 20, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS